Related Experiment Videos
[Study on the toxicity and antitumor activity of adriamycin-DNA and amsacrine-DNA complexes in mice]
Abstract:
We have compared in vitro binding of adriamycin (ADR) and amsacrine (AMSA) with DNA, the toxicity, and the antitumor activity of ADR-DNA and AMSA-DNA, after intraperitoneal (ip) injection in mice. The binding of ADR with DNA is 100-fold higher than that of AMSA with DNA. The overall toxicity of ADR-DNA is significantly lower than that of ADR. ADR-DNA is more effective than ADR against three models of S180 sarcoma (by sc, ip and i.v. inoculation into mice). The peak levels of ADR-DNA and ADR were 265 +/- 24 ng.ml-1 versus 108 +/- 16 ng.ml-1 (P < 0.01). AUC 0-12 h were 1064 +/- 84 ng.h-1 x ml-1 versus 382 +/- 27 ng.h-1 x ml-1 (P < 0.01). The levels of ADR in most of tissues and tumor after administration of ADR-DNA were higher than those after administration of ADR. Moreover, there is no difference in toxicity, therapeutic effects as well as AUC between AMSA-DNA and AMSA.
Insights
Adriamycin-DNA conjugate shows reduced toxicity and enhanced antitumor activity compared to free adriamycin. Amsacrine-DNA conjugate demonstrated no significant differences from free amsacrine in efficacy or toxicity.
Area of Science:
- Pharmacology
- Molecular Biology
- Oncology
Context:
- Adriamycin (ADR) and amsacrine (AMSA) are established anticancer agents.
- Drug delivery systems are crucial for improving therapeutic indices of chemotherapeutics.
- DNA-conjugated forms of these drugs may alter their pharmacokinetic and pharmacodynamic properties.
Purpose:
- To compare the in vitro DNA binding, toxicity, and in vivo antitumor activity of adriamycin-DNA (ADR-DNA) and amsacrine-DNA (AMSA-DNA) conjugates against S180 sarcoma in mice.
- To evaluate the pharmacokinetic profiles of ADR-DNA and ADR following intraperitoneal injection.
Summary:
- ADR exhibits 100-fold higher DNA binding affinity than AMSA in vitro.
- ADR-DNA demonstrates significantly lower toxicity and superior efficacy against S180 sarcoma models compared to free ADR.
- ADR-DNA exhibits higher peak plasma levels and AUC (0-12h) than ADR, with increased drug distribution to tissues and tumors.
- AMSA-DNA shows no significant differences in toxicity, therapeutic effects, or AUC compared to free AMSA.
Impact:
- ADR-DNA represents a promising strategy for enhancing the therapeutic efficacy and safety of adriamycin in cancer treatment.
- The findings suggest that DNA conjugation may be a viable approach for optimizing ADR delivery, but not necessarily for AMSA.
- Further research into drug-DNA conjugates could lead to novel chemotherapeutic formulations with improved clinical outcomes.